MedTrace Logo

Role of Cryobiopsy in Diagnosis of Pleural Effusion

NCT03828903 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-12-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, size and quality of the specimens obtained by cryoprobe in comparison to those specimens obtained by flexible forceps during medical thoracoscopy in diagnosis of pleural effusion.

Conditions

  • Pleural Effusion

Interventions

DEVICE

Cryoprobe

* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization. * The tip of the cryoprobe will be attached to suspicious part of parietal pleura . * The frozen tissue is going to be extracted by gently pulling of the probe. * Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture. * The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. * The biopsy sample will be released from the probe by thawing in the saline. * The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Reham M El morshedy, Lecturer · Assiut University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-10
Primary Completion
2021-09-10
Completion
2021-10-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03828903 on ClinicalTrials.gov